Cidara Therapeutics : Corporate Presentation - October 2020

New Hope for Serious Infections

Corporate Presentation

October 2020

© Cidara Therapeutics 2020

Forward-looking statements

potential for long-term single dose protection, and a

broad

safety

margin;

and

These slides contain

sales, and whether it

will be more valuable than other

whether Cidara's Cloudbreak platform will identify

AVCs resulting in therapies that are fast acting and

types of anti-infectives; statements about the potential

forward-looking

effectiveness,

safety,

and

long-acting

nature

long acting; whether Cidara's HIV approach will yield

similar

results

in

its coronavirus AVCs,

and

of rezafungin,

whether preclinical tissue penetration

whether Cidara can successfully identify AVCs to

statements within the

data will be seen in patients, and whether it will

inhibit viral fusion in coronavirus. This presentation

meaning of the Private

enable fast clearance of infection, the early discharge

also contains estimates and other statistical data

of hospitalized patients, or transform the care of BMT

Securities Litigation

patients; whether the results of the STRIVE clinical trial

made by independent parties and by Cidara relating

to market size and growth and other data about

or the post-hoc analysis indicates a successful outcome

Reform Act of 1995.

in the Phase 3 ReSTORE clinical trial, including whether

Cidara's industry. These data involve a number of

assumptions and limitations, and you are cautioned

or not rezafungin will meet the primary endpoints in

not

to

give

undue

weight

to such

estimates.

the ReSTORE trial; and the ability of Cidara to achieve

These slides are not intended to and do not

Projections, assumptions and estimates of the future

all milestones from

its

collaboration

partner

performance of the markets in which Cidara operates

constitute an offer to sell or the solicitation

for rezafungin,

Mundipharama,

and receive related

are

necessarily subject to a high degree of

of an offer to

subscribe

for

or

buy or

an

payments.

Certain

statements

regarding

our

uncertainty and risk, including, Cidara's ability to

invitation to purchase or subscribe for any

Cloudbreak platform are also forward-looking including

obtain additional financing; the success and timing of

securities in any jurisdiction, nor shall there

statements

regarding

whether

Cidara

can

develop

Cidara's preclinical studies, clinical trials and other

be any sale, issuance or transfer of securities

single-dose, long acting antiviral conjugates (AVCs) for

research and development activities; receipt of

in

any

jurisdiction

in

contravention

of

respiratory

disease;

whether

Cidara's

Cloudbreak

necessary regulatory approvals for development and

applicable law. No offer of securities shall be

platform can identify product candidates with intrinsic

commercialization, as well as changes to applicable

made except by

means

of

a

prospectus

antimicrobial activity

and immune engagement

that

regulatory laws in the United States and foreign

meeting the requirements of Section 10 of

will increase efficacy or represent an improvement over

countries; changes in Cidara's plans to develop and

the

Securities

Act

of

1933,

as

amended.

existing

anti-infective

agents;

whether

Cloudbreak

commercialize its product candidates; Cidara's ability

Because such statements are subject to risks

influenza candidates, including CD377, will achieve the

to

obtain

and

maintain

intellectual

property

and uncertainties, actual results may differ

major attributes believed to be needed in flu such as

protection for its product candidates; and the loss of

materially from those expressed or implied

broad spectrum, superior resistance profile, protection

key scientific or management personnel

and

the

by

such

forward-looking

statements. Such

for high-risk

populations, expanded efficacy

window,

impacts of global health crises, including the current

statements include,

but

are not

limited

long duration of action and rapid onset of activity, or

COVID-19 pandemic.. These and other risks and

to,

statements

regarding

whether

Cidara's

flexible

administration;

whether

results

observed in

uncertainties are described more fully in Cidara's

antifungal and antiviral research will result in

preclinical

studies

with

Cloudbreak

influenza

Form 10-Q as most recently filed with the United

therapies

that

are

superior

to

other

candidates,

including

CD377,

will

be

observed in

States Securities and Exchange Commission (SEC),

products;

whether

Cidara's

approach

to

human use or represent an improvement over existing

under the heading "Risk Factors." All forward-looking

infectious

disease

will

be

transformative

therapies, including potency and potency against highly

statements contained in this presentation speak only

and

whether

Cidara's

product

candidates

resistant influenza strains, lower resistance, protection

as of the date on which they were made. Cidara

may be successfully

developed

to

address

in immune compromised hosts, the ability to extend

undertakes no obligation to update such statements

unmet

medical

needs;

the treatment

window, efficacy in

multiple dosing

to reflect events

that occur

or circumstances that

whether Cidara can successfully commerciali-

routes,

exist after the date on which they were made.

ze rezafungin, achieve projected peak

2

Cidara investment thesis

Leading science on long-acting antifungal and antiviral prevention and treatment

	Rezafungin		1st antifungal in 14 years for 1st line treatment and prophylaxis
		Treatment - Phase 3		ReSTORE: treatment of candidemia and invasive candidiasis
		Prophylaxis - Phase 3		ReSPECT: prevention in high risk hematology (BMT) setting
		Validation		Significant ex-US/ex-Japan partnership with Mundipharma
	Cloudbreak AVCs		Modular antiviral platform for prevention & treatment
		Influenza A+B		Target: 1st effective 'universal flu' product

3

Leading the science on antifungal & antiviral prevention & treatment

					IND-
Program	Proposed Indication	Discov.	in-vitro	in-vivo	enable	Ph 1	Ph 2	Ph 3

ANTIFUNGAL: Long acting treatment and prevention

Treatment of

Rezafungin Candidemia &

Invasive Candidiasis

Prophylaxis of IFD in

Rezafungin Blood & Marrow

Transplant Patients

ANTIVIRAL: Cloudbreak® Antiviral Conjugates (AVCs) for rapid treatment and long-term prevention

CD377	Influenza
Single-dose/~4months
	Prevention & Treatment
CD388	Influenza
Single-dose/~6months
	Prevention & Treatment
RSV AVC	RSV
Prevention & Treatment
HIV AVC	HIV
PEP, PrEP, Maintenance
CoV AVC	COVID-19 & Pan CoV	4
Prevention & Treatment